TP53-related clonal competition and disrupted molecular processes in CLL

Warning

This publication doesn't include Institute of Computer Science. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	TAUŠOVÁ Kristýna PORC Jakub Paweł TAUŠ Petr PÁL Karol MALČÍKOVÁ Jitka PAVLOVÁ Šárka STRÁNSKÁ Kamila ŽENATOVÁ Marcela TICHÝ Boris PANOVSKÁ Anna DOUBEK Michael POSPÍŠILOVÁ Šárka PLEVOVÁ Karla
Year of publication	2024
Type	Conference abstract
MU Faculty or unit	Central European Institute of Technology
Citation
Attached files	TP53-related_clonal_competition.pdf
Description	The presence of either TP53 gene loss or mutation defined high-risk CLL especially in the era of chemoimmunotherapy. Its prognostic and predictive impact remains a matter of debate in the setting of BTKi- and BCL2i-based treatment, which does not act directly via the TP53 pathway, but yet seems to associate with worse clinical outcomes. The adverse effect on overall survival, at least upon chemoimmunotherapy, is notable not only in patients with expanded but also in lowburden TP53 mutations, which were identified in 5–35% of CLL patients. In this study, we aimed to scrutinize the principles of clonal competition in CLL and identify factors influencing the development of TP53-mutated subclones in various clinical contexts.
Related projects:	National institute for cancer research Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit XI A variety of TP53 aberrant states in the clinical and biological behavior of chronic lymphocytic leukemia cells